Related Experiment Video
Updated: Jan 26, 2026

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
Published on: February 28, 2014
Designing circulating tumor DNA-based interventional clinical trials in oncology
Daniel V Araujo1, Scott V Bratman2, Lillian L Siu3
1Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
Abstract:
Circulating tumor (ct) DNA is a powerful tool that can be used to track cancer beyond a single snapshot in space and time. It has potential applications in detecting minimal residual disease and predicting relapse, in selecting patients for tailored treatments, and in revealing mechanisms of response or resistance. Here, we discuss the incorporation of ctDNA into clinical trials.
Insights
Circulating tumor DNA (ctDNA) offers a dynamic way to monitor cancer progression and treatment response. This powerful tool is being integrated into clinical trials for improved patient management and therapeutic strategies.
Area of Science:
- Oncology
- Molecular Biology
- Clinical Research
Background:
- Circulating tumor DNA (ctDNA) provides a non-invasive method for real-time cancer monitoring.
- ctDNA analysis has shown promise in various oncological applications.
- Integrating ctDNA into clinical trials is a critical next step for its widespread adoption.
Purpose of the Study:
- To discuss the incorporation of ctDNA analysis into clinical trial designs.
- To highlight the potential applications of ctDNA in oncology.
- To explore how ctDNA can enhance patient stratification and treatment monitoring.
Main Methods:
- Review of current literature and clinical trial methodologies.
- Discussion of ctDNA's role in detecting minimal residual disease and predicting relapse.
- Analysis of ctDNA's utility in patient selection for targeted therapies.
Main Results:
- ctDNA can track cancer dynamics beyond single time points.
- Potential for ctDNA in early detection of relapse and guiding treatment decisions.
- ctDNA aids in understanding mechanisms of treatment response and resistance.
Conclusions:
- ctDNA is a valuable biomarker for cancer management.
- Incorporating ctDNA into clinical trials will accelerate its therapeutic use.
- Further research and standardization are needed for optimal ctDNA implementation.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Community Based Intervention
Foundations of Community Mental Health Programs
Central to the success of community-based interventions is the...
Statistical Software for Data Analysis and Clinical Trials
DNA Base Pairing
DNA Base Pairing

